Azitra Secures U.S. Patent No. 12,606,610 B2 for ATR-12 Phase 1b Netherton Syndrome Therapy
Azitra received U.S. Patent No. 12,606,610 B2 on April 21, 2026, granting broad protection for its lead candidate ATR-12, an engineered S. epidermidis strain expressing LEKTI protein for treating Netherton syndrome. ATR-12 is currently in a Phase 1b trial targeting a patient pool of approximately 20,000 globally.
1. Patent Details
On April 21, 2026, the U.S. Patent Office issued Patent No. 12,606,610 B2 covering compositions and methods for treating skin diseases with genetically engineered S. epidermidis strains that secrete domains of the LEKTI protein. This patent provides broad protection for Azitra’s ATR-12 program, underpinning its exclusivity in developing live biotherapeutic treatments for Netherton syndrome and related disorders.
2. Phase 1b Clinical Trial
ATR-12, Azitra’s lead candidate, is undergoing a Phase 1b trial in adult patients with Netherton syndrome, a rare and potentially fatal skin disease affecting an estimated 20,000 individuals worldwide. The trial evaluates safety, tolerability and preliminary efficacy of the engineered microbial therapy, with topline data expected later this year.
3. Strategic Implications
Securing this patent strengthens Azitra’s intellectual property portfolio and de-risks its lead program by extending market exclusivity. The enhanced IP position could boost investor confidence and valuation as Azitra advances ATR-12 alongside its fast-track ATR-04 program for EGFR inhibitor–associated rash.